Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Clinical Chemistry and Laboratory Medicine|November 6, 2003
Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulinAndreas Pfützner, Thomas Kunt, Matthias Langenfeld, et al.
Diabetes & Vascular Disease Research|April 13, 2010
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA studyThomas Schöndorf, Georg Lübben, Efstrathios Karagiannis, et al.
Experimental Diabetes Research|May 17, 2008
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patientsThomas Hach, Thomas Forst, Thomas Kunt, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Reliability of lightguide spectrophotometry (O2C) for the investigation of skin tissue microvascular blood flow and tissue oxygen supply in diabetic and nondiabetic subjectsThomas Forst, Cloth Hohberg, Eda Tarakci, et al.
Journal of Diabetes Science and Technology|July 12, 2022
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical TrialsLutz Heinemann, Melanie Davies, Philip Home, et al.
Journal of Diabetes Science and Technology|January 9, 2013
No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label studyThomas Danne, Thomas Forst, Jürgen Deinhard, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III studyThomas Schöndorf, Andreas Pfützner, Georg Lübben, et al.
Journal of Diabetes and Its Complications|April 25, 2006
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapyChristof Kazda, Hiltrud Hülstrunk, Karin Helsberg, et al.
Diabetes Technology & Therapeutics|May 23, 2009
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditionsThomas Schöndorf, Efstrathios Karagiannis, Richard E K Posseldt, et al.
Diabetes, Obesity & Metabolism|June 22, 2016
Euglycaemic glucose clamp: what it can and cannot do, and how to do itTim Heise, Eric Zijlstra, Leszek Nosek, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Clinical Chemistry and Laboratory Medicine|November 6, 2003
Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulinAndreas Pfützner, Thomas Kunt, Matthias Langenfeld, et al.
Diabetes & Vascular Disease Research|April 13, 2010
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA studyThomas Schöndorf, Georg Lübben, Efstrathios Karagiannis, et al.
Experimental Diabetes Research|May 17, 2008
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patientsThomas Hach, Thomas Forst, Thomas Kunt, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Reliability of lightguide spectrophotometry (O2C) for the investigation of skin tissue microvascular blood flow and tissue oxygen supply in diabetic and nondiabetic subjectsThomas Forst, Cloth Hohberg, Eda Tarakci, et al.
Journal of Diabetes Science and Technology|July 12, 2022
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical TrialsLutz Heinemann, Melanie Davies, Philip Home, et al.
Journal of Diabetes Science and Technology|January 9, 2013
No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label studyThomas Danne, Thomas Forst, Jürgen Deinhard, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III studyThomas Schöndorf, Andreas Pfützner, Georg Lübben, et al.
Journal of Diabetes and Its Complications|April 25, 2006
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapyChristof Kazda, Hiltrud Hülstrunk, Karin Helsberg, et al.
Diabetes Technology & Therapeutics|May 23, 2009
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditionsThomas Schöndorf, Efstrathios Karagiannis, Richard E K Posseldt, et al.
Diabetes, Obesity & Metabolism|June 22, 2016
Euglycaemic glucose clamp: what it can and cannot do, and how to do itTim Heise, Eric Zijlstra, Leszek Nosek, et al.
Pageof 15